arrow
Y

Yong Mao

Department of Oncology
H指数:42
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

First-line anlotinib versus bevacizumab plus CapeOX in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ANCHOR): a multicenter, prospective, randomized, phase 3 trial

ANCHOR研究:一线安罗替尼与贝伐珠单抗联合卡培他滨/奥沙利铂治疗RAS/BRAF野生型不可切除转移性结直肠癌的多中心、前瞻性、随机、III期临床试验

2026-09-010
OA
Flipping of a Non-productive Substrate Binding Conformation Facilitates Hydroxynitrile Lyase Catalyzed Hydrocyanation

非活性底物结合构象的翻转促进了羟基腈裂解酶催化的氰化反应

2025-10-240
PRE
Non-invasive imaging of CLDN18.2 expression in gastric adenocarcinoma: synthesis, preclinical evaluation, and preliminary clinical study of a novel [89Zr]Zr-DFO-NY005 ImmunoPET tracer

非侵入性成像CLDN18.2在胃癌腺癌中的表达:一种新型[89Zr]Zr-DFO-NY005免疫PET示踪剂的合成、临床前评估和初步临床研究

2025-09-220
PRE
A pan-KRAS degrader for the treatment of KRAS-mutant cancers

用于治疗KRAS突变癌症的pan-kras降解剂

2024-06-281
OAAI
Hetrombopag for the management of chemotherapy-induced thrombocytopenia in patients with advanced solid tumors: a multicenter, randomized, double-blind, placebo-controlled, phase II study
2024-06-140
OAAI